Literature DB >> 24931823

Intraoperative target-controlled infusion anesthesia application using remifentanil hydrochloride with etomidate in patients with severe burn as monitored using Narcotrend.

Zhenggang Guo1, Liwei Pang1, Xiaopeng Jia1, Xiaoyan Wang1, Xiaojun Su1, Ping Li1, Weidong Mi2, Jianhua Hao3.   

Abstract

OBJECTIVE: This study aims to evaluate the feasibility of intraoperative composite target-controlled infusion (TCI) anesthesia application using remifentanil hydrochloride with etomidate in patients with severe burns, as monitored by Narcotrend.
METHODS: A total of 40 patients with severe burns with eschar excisions and skin grafts were randomly and equally grouped into the etomidate (E) and the propofol groups (P). Anesthesia was induced and maintained by a remifentanil hydrochloride TCI combined with etomidate or propofol. The depth of anesthesia and other relevant indicators were recorded through intraoperative electroencephalogram monitoring using a Narcotrend monitor.
RESULTS: No statistically significant differences were observed between the drug withdrawal times, eye opening requirements, or orientation recoveries of the two groups (P>0.05). The cortisol and aldosterone levels in group E were significantly lower than those in group P 24h post operation (P<0.05). No significant differences between the number of operations, hospitalization duration, mean arterial pressure, heart rate, and postoperative adverse reaction incidence of the two groups were observed at each time point (P>0.05).
CONCLUSION: The application of a composite remifentanil hydrochloride combined with etomidate TCI is feasible for the early eschar excision in patients with severe burns.
Copyright © 2014 Elsevier Ltd and ISBI. All rights reserved.

Entities:  

Keywords:  Etomidate; Narcotrend; Severe burns; Stress response; Target-control infusion

Mesh:

Substances:

Year:  2014        PMID: 24931823     DOI: 10.1016/j.burns.2014.04.021

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  7 in total

1.  Pharmacodynamic analysis of target-controlled infusion of propofol in patients with hepatic insufficiency.

Authors:  Jing-Ru Pan; Jun Cai; Shao-Li Zhou; Qian-Qian Zhu; Fei Huang; Yi-Han Zhang; Xin-Jin Chi; Zi-Qing Hei
Journal:  Biomed Rep       Date:  2016-10-19

2.  Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis.

Authors:  Jian-Yan Chen; Ming Yi; Shang-Long Yao; Xue-Ping Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-05

3.  Assessment of different loading doses of dexmedetomidine hydrochloride in preventing adverse reaction after combined spinal-epidural anesthesia.

Authors:  Wanwei Jiang; Qinghui Wang; Min Xu; Yu Li; Rui Yang; Xiaoyang Song; Haixia Duan; Pengbo Zhang
Journal:  Exp Ther Med       Date:  2017-04-13       Impact factor: 2.447

4.  Moderate hypercapnia may not contribute to postoperative delirium in patients undergoing bronchoscopic intervention.

Authors:  Qinghao Cheng; Lei Li; Mingyuan Yang; Lei Sun; Renjiao Li; Rui Huang; Jun Ma
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Systematic review and meta-analysis of the prognostic value of Narcotrend monitoring of different depths of anesthesia and different Bispectral Index (BIS) values for cognitive dysfunction after tumor surgery in elderly patients.

Authors:  Xinhua Shi; Xiangnan Chen; Jun Ni; Yanqing Zhang; Hui Liu; Chuan Xu; Hao Wang
Journal:  Ann Transl Med       Date:  2022-02

6.  Etomidate in neuroanesthesia for aneurysmal clipping in child with confirmed allergies to general anesthetics.

Authors:  Vasilije Stambolija; Martina Miklic Bublic; Marin Lozic; Josip Paladino; Miroslav Šcap
Journal:  Surg Neurol Int       Date:  2018-10-03

7.  Remifentanil inhibits the traumatic stress response in emergent trauma surgery.

Authors:  Ru Ouyang; Haijing Ren; Wei Liu; Xi Yuan; Enjun Lei
Journal:  J Clin Lab Anal       Date:  2019-08-02       Impact factor: 3.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.